We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend king stocks to invest in now.
Investing in dividend stocks has been a focal point for investors for several years. The attractive income generated from these stocks motivates many to invest. Among these, dividend growth stocks stand out, as they offer the potential for increasing income over time, which is highly appealing. In the US, numerous companies have consistently raised their dividends for over five decades, earning them the prestigious title of Dividend Kings.
Analysts have long supported dividend stocks due to their historically robust performance. Kirsten Cabacungan, an investment strategist at Merrill and Bank of America Private Bank, has highlighted several reasons to consider investing in these stocks. She pointed out that the income generated by dividend stocks can assist investors in meeting their liquidity needs. In addition, dividend-focused investments have shown a tendency to reduce volatility and mitigate losses during market downturns. Cabacungan particularly emphasizes the value of dividend growth stocks in this context. Here are some comments from the analyst:
“Companies that have consistently increased their dividends tend to be more stable, higher-quality businesses, which historically have weathered downturns and are more likely to have the ability to pay dividends consistently.”
In 2024, dividend stocks lagged behind the broader market, but their future remains promising. Analysts are optimistic about a rebound, as cash flow remains a key priority for investors. Capital Group has advised looking for opportunities in overlooked dividend-paying companies, such as pharmaceutical firms overshadowed by the focus on weight loss treatments, as well as utilities and select banks. In addition, dividend growth stocks with substantial yields continue to attract interest. Companies offering dividends alongside strong balance sheets and appealing yields can deliver steady income, cushion against market downturns, and foster solid investment growth. A report from ProShares noted that the Dividend Aristocrats Index has historically outperformed the broader market with less volatility. For example, a $10,000 investment in May 2005 could have grown to more than $61,000 by March 2023.
Also read: 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds
Investor preferences have led many US companies to increase and sustain their dividends in 2024. Financial experts anticipate continued dividend growth in 2025. Howard Silverblatt, a senior index analyst at S&P Dow Jones Indices, predicts an average dividend increase of around 8% for the current year. He expects another record payout in 2025, estimated at approximately $685 billion, compared to the projected $630 billion for 2024. Silverblatt attributes this growth to record earnings, anticipated future earnings, declining interest rates, strong employment, and overall economic growth.
In addition, the broader market’s dividend yield has recently hit a 20-year low, dipping below 1.19%, well below the long-term average of 4.3%. As interest rates rise on risk-free options like Treasuries, companies are increasingly aware of the competition for yield. In response, many are boosting their dividends or starting to offer them for the first time. Notably, several major tech firms began paying dividends in 2024, indicating their intention to position themselves as value investments within the traditionally high-growth tech sector. Given this, we will take a look at some of the best dividend kings to invest in.
Our Methodology:
For this list, we reviewed the Dividend Kings companies and selected the ten stocks that were most favored by hedge funds in the third quarter of 2024, using data from Insider Monkey’s database. The stocks are ranked by the number of hedge fund investments, starting with the lowest.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.
AbbVie Inc. (NYSE:ABBV)
Number of Hedge Fund Holders: 68
AbbVie Inc. (NYSE:ABBV) is an American biopharmaceutical company that specializes in the development and commercialization of advanced therapies and treatments in various areas of healthcare.
Analysts are optimistic about the company’s future growth, with expectations that it will rely heavily on two blockbuster drugs, Skyrizi and Rinvoq, in the years ahead. These drugs generated over $4.8 billion in revenue during Q3 2024 and are projected to exceed $27 billion in annual sales by 2027, targeting conditions such as rheumatology, dermatology, psoriatic diseases, and inflammatory bowel disorders.
AbbVie Inc. (NYSE:ABBV) reported a total revenue of $14.46 billion for Q3 2024, a 4% increase compared to the previous year. Its Immunology Portfolio contributed more than $7 billion, also growing by 4%. Moreover, in August 2024, the company completed an $8.7 billion acquisition of Cerevel Therapeutics, a neuroscience company, which strengthened its pipeline with promising treatments, including emraclidine, a potential therapy for schizophrenia.
This was also highlighted by Polaris Capital Management in its Q3 2024 investor letter:
“U.S. biopharma/biotech companies topped the health care sector, with the majority of holdings posting returns in excess of 10%. AbbVie Inc. (NYSE:ABBV) showed positive top-line growth from its immunosuppressive drugs, Skyrizi and Rinvoq. Abbvie’s management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.”
AbbVie Inc. (NYSE:ABBV) has a strong dividend history with 52 consecutive years of dividend growth under its belt. Moreover, the company has raised its payouts at an annual average rate of nearly 8% in the past five years. Currently, it pays a quarterly dividend of $1.64 per share and has a dividend yield of 3.71%, as of January 13.
Of the 900 hedge funds tracked by Insider Monkey at the end of Q3 2024, 68 funds held stakes in AbbVie Inc. (NYSE:ABBV), up from 67 in the preceding quarter. These stakes have a total value of nearly $2.6 billion. With over 1.7 million shares, AQR Capital Management was the company’s leading stakeholder in Q3.
Overall, ABBV ranks 6th on our list of best dividend king stocks to invest in now. While we acknowledge the potential for ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
